Actrapid Hm

Actrapid HM: description of the drug and its characteristics

Actrapid HM is a short-acting insulin used to treat diabetes. This drug is produced by several companies, including Bryntsalov (Russia), Novo Nordisk A/O (Denmark) and Torrent Pharmaceuticals (India).

The manufacturing country of Actrapid HM is Russia, Denmark and India. The pharmaceutical group to which the medicine belongs is short-acting insulins. This means that Actrapid HM acts quickly, providing a rapid decrease in blood glucose levels after administration.

The international name of Actrapid HM is soluble insulin (human genetically engineered). This drug is also known by several synonyms, including Actrapid HM penfil, Biosulin R, Gansulin R, Insulin Humulin R, Insulin Humulin Regular, Human insulin, Human insulin suspension, Insuman Rapid GT, Insuran R, Humulin R, Humulin Regular and Humulin Regular.

Actrapid HM is available in several dosage forms, including 40 IU/mL injection, 40 IU/mL injection, and 100 IU/mL injection.

Actrapid HM is used to control blood glucose levels in patients with type 1 and type 2 diabetes. This short-acting insulin is intended to be administered subcutaneously, usually before meals. The dosage may vary depending on the individual needs of the patient and should be determined by the physician.

Overall, Actrapid HM is an effective medicine for controlling blood glucose levels in diabetic patients. However, before you start taking this drug, you should consult your doctor and strictly follow the dosage and use recommendations.